Cardiovascular Systems unveils 1-year data from its ORBIT II study, reporting positive safety and efficacy outcomes as well as significant cost-savings for the Diamondback 360 atherectomy device. Minnesota-based Cardiovascular Systems (NSDQ:CSII) this week unveiled 1-year outcomes of a pivotal study of its Diamondback 360 device in treating coronary artery disease. The device continued to demonstrate long-term safety and effectiveness in treating coronary blockages and the treatment generated more than $4,000 per patient in cost-savings thanks to shorter hospital stays and a lower rate of readmissions, researchers said.
Help employers find you! Check out all the jobs and post your resume.
